Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd M Morgan

Showing results (101-110 of 307) with videos related to

Pageof 31
Sort By:
Urologic Oncology|December 4, 2019
Should all prostate needle biopsy Gleason score 4 + 4 = 8 prostate cancers be high risk? Implications for shared decision-making and patient counsellingKevin Ginsburg, Adam I Cole, Michael E Silverman, et al.
European Urology|May 18, 2023
2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic ReviewOskar Bergengren, Kelly R Pekala, Konstantina Matsoukas, et al.
JCO Precision Oncology|June 6, 2025
Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell CarcinomaSteven M Monda, Srinivas Nallandhighal, Ulka Vaishampayan, et al.
Oncotarget|March 31, 2016
Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrowYounghun Jung, Ann M Decker, Jingcheng Wang, et al.
European Urology Oncology|May 18, 2019
Staging the Host: Personalizing Risk Assessment for Radical Cystectomy PatientsSarah P Psutka, Daniel A Barocas, James W F Catto, et al.
The Journal of Urology|July 27, 2011
Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomyTodd M Morgan, Kirk A Keegan, Daniel A Barocas, et al.
Cancers|December 9, 2023
Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune PhenotypeMark Farha, Srinivas Nallandhighal, Randy Vince, et al.
BJU International|September 11, 2012
ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinomaSamuel D Kaffenberger, Todd M Morgan, Kelly L Stratton, et al.
Urology Practice|May 5, 2023
Delayed Urological Cancer Care during the COVID-19 Pandemic: Urologists' ExperienceDaniela Wittmann, Anna Faris, James E Montie, et al.
Urologic Oncology|December 3, 2014
Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinomaSamuel D Kaffenberger, Opal Lin-Tsai, Kelly L Stratton, et al.
Pageof 31

Showing results (101-110 of 307) with videos related to

Sort By:
Pageof 31
Urologic Oncology|December 4, 2019
Should all prostate needle biopsy Gleason score 4 + 4 = 8 prostate cancers be high risk? Implications for shared decision-making and patient counsellingKevin Ginsburg, Adam I Cole, Michael E Silverman, et al.
European Urology|May 18, 2023
2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic ReviewOskar Bergengren, Kelly R Pekala, Konstantina Matsoukas, et al.
JCO Precision Oncology|June 6, 2025
Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell CarcinomaSteven M Monda, Srinivas Nallandhighal, Ulka Vaishampayan, et al.
Oncotarget|March 31, 2016
Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrowYounghun Jung, Ann M Decker, Jingcheng Wang, et al.
European Urology Oncology|May 18, 2019
Staging the Host: Personalizing Risk Assessment for Radical Cystectomy PatientsSarah P Psutka, Daniel A Barocas, James W F Catto, et al.
The Journal of Urology|July 27, 2011
Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomyTodd M Morgan, Kirk A Keegan, Daniel A Barocas, et al.
Cancers|December 9, 2023
Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune PhenotypeMark Farha, Srinivas Nallandhighal, Randy Vince, et al.
BJU International|September 11, 2012
ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinomaSamuel D Kaffenberger, Todd M Morgan, Kelly L Stratton, et al.
Urology Practice|May 5, 2023
Delayed Urological Cancer Care during the COVID-19 Pandemic: Urologists' ExperienceDaniela Wittmann, Anna Faris, James E Montie, et al.
Urologic Oncology|December 3, 2014
Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinomaSamuel D Kaffenberger, Opal Lin-Tsai, Kelly L Stratton, et al.
Pageof 31